Enhancer of Zeste Homolog 2 (EZH2) in Malignant Progression of Gallbladder Carcinoma.
Carcinoma
DNMT
Dysplasia
EZH2
Epigenetic
Gallbladder
H3K27me3
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
06
10
2020
pubmed:
15
10
2020
medline:
13
1
2022
entrez:
14
10
2020
Statut:
ppublish
Résumé
Data related to the role of epigenetic modifications in gallbladder carcinoma (GBC) is limited. We intended to assess the role of crucial epigenetic modifiers pertaining to histone modification and DNA-methylation system in gallbladder carcinogenesis. The expression of EZH2, H3K27me3, and DNA methyltransferases (DNMTs) was analyzed by immunohistochemistry in cases of GBC (n = 39), gallbladder dysplasia (GBD, n = 12), and benign mucosa (BM, n = 16). A semi-quantitative scoring system was used for assessing the immunohistochemical expression. The expression of EZH2 was significantly higher in cases of GBC than GBD (p value 0.001). The cases of BM were negative. Its expression was also higher in poorly differentiated tumors and positively correlated with the proliferative activity (MIB-1 labeling index) (p value 0.03 and 0.01, respectively). There was no significant difference in the expression levels of H3K27me3, DNMT-1, and DNMT-3B among GBC, GBD, and BM cases. Although GBC cases with strong EZH2 expression showed a shorter overall survival, the difference was not statistically significant. This study highlights the crucial role of the key epigenetic regulators EZH2 in the pathobiology and evolution of gallbladder carcinogenesis. Given the reversibility of epigenetic alterations, EZH2 may be a novel therapeutic target for gallbladder carcinogenesis.
Identifiants
pubmed: 33051796
doi: 10.1007/s12029-020-00536-3
pii: 10.1007/s12029-020-00536-3
doi:
Substances chimiques
Biomarkers, Tumor
0
Histones
0
histone H3 trimethyl Lys4
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1034Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5(2):93–102.
doi: 10.5114/ceh.2019.85166
Kim YJ, Kim K. Conditional survival in patients with gallbladder cancer. Chin J Cancer. 2017;36(1):85.
doi: 10.1186/s40880-017-0252-1
Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–9.
doi: 10.1038/nature09784
Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001;20(24):3139–55.
doi: 10.1038/sj.onc.1204341
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11.
doi: 10.1073/pnas.1933744100
Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(24 Pt 1):8570–6.
doi: 10.1158/1078-0432.CCR-05-1047
Toll AD, Dasgupta A, Potoczek M, Yeo CJ, Kleer CG, Brody JR, et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010;41(9):1205–9.
doi: 10.1016/j.humpath.2010.03.004
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9.
doi: 10.1038/nature01075
Weikert S, Christoph F, Köllermann J, Müller M, Schrader M, Miller K, et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005;16(2):349–53.
pubmed: 16012774
Lee HW, Choe M. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker. Pathol Int. 2012;62(11):735–41.
doi: 10.1111/pin.12001
Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer. 2005;92(9):1754–8.
doi: 10.1038/sj.bjc.6602531
Han Li C, Chen Y. Targeting EZH2 for cancer therapy: progress and perspective. Curr Protein Pept Sci. 2015;16(6):559–70.
doi: 10.2174/1389203716666150409100233
Fattahi S, Golpour M, Amjadi-Moheb F, Sharifi-Pasandi M, Khodadadi P, Pilehchian-Langroudi M, et al. DNA methyltransferases and gastric cancer: insight into targeted therapy. Epigenomics. 2018;10(11):1477–97.
doi: 10.2217/epi-2018-0096
Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33(8):2989–96.
pubmed: 23898051
Ding WJ, Fang JY, Chen XY, Peng YS. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci. 2008;53(8):2083–9.
doi: 10.1007/s10620-007-0145-2
He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, et al. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev. 2012;13(7):3173–8.
doi: 10.7314/APJCP.2012.13.7.3173
Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70(4):1430–40.
doi: 10.1158/0008-5472.CAN-09-2755
Yamaguchi J, Sasaki M, Harada K, Zen Y, Sato Y, Ikeda H, et al. Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin. Lab Investig. 2009;89(9):1018–31. https://doi.org/10.1038/labinvest.2009.65 .
doi: 10.1038/labinvest.2009.65
pubmed: 19564843
Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, et al. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci. 2010;101(2):355–62.
doi: 10.1111/j.1349-7006.2009.01387.x
Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract. 2011;207(8):472–8.
doi: 10.1016/j.prp.2011.05.010
Lin B, Hong H, Jiang X, Li C, Zhu S, Tang N, et al. c-Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer. Mol Med Rep. 2018;17(6):8180–8.
pubmed: 29693707
pmcid: 5983991
Srivastava K, Srivastava A, Mittal B. DNMT3B-579 G > T promoter polymorphism and risk of gallbladder carcinoma in North Indian population. J Gastrointest Cancer. 2010;41(4):248–53.
doi: 10.1007/s12029-010-9156-x
Honeywell RJ, Sarkisjan D, Kristensen MH, de Klerk DJ, Peters GJ. DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors. Nucleosides Nucleotides Nucleic Acids. 2018;37(12):696–708.
doi: 10.1080/15257770.2018.1498516